natgillin/translations-raw huggingface dataset:
Den dosis, som I-Neb AAD-systemet lever, kontrolleres af medicineringskammeret i kombination med en kontroldisk.
The dose delivered by the I-Neb AAD system is controlled by the medication chamber in combination with a control disc.
Den dosis, som I-Neb AAD-systemet leverer, kontrolleres af medicineringskammeret i kombination med en kontroldisk.
The dose delivered by the I-Neb AAD system is controlled by the medication chamber in combination with a control disc.
Den dosis, som skal anvendes, beregnes ud fra dyrets vægt.
The dose to use is calculated according to the animal’s weight.
Den dosisbegrænsende toksicitet i disse studier var primært hæmatologisk.
The dose limiting toxicity in these studies was essentially haematological.
Den dødelige dosis ASA er 25-30 g.
The lethal dose of acetylsalicylic acid is 25-30 g.
Den effektive dosis som følge af indgift af 185 MBq DaTSCAN injektion er 4,35 mSv (per 70 kg person).
The effective dose (E) resulting from administration of 185 MBq of DaTSCAN injection is 4.35 mSv (per 70 kg individual).
Den effektive gennemsnitlige eliminations- halveringstid for tipranavir med ritonavir hos raske frivillige (n=67) og hiv-inficerede voksne patienter (n=120) var hhv. ca.
The effective mean elimination half-life of tipranavir with ritonavir in healthy volunteers (n = 67) and
Den efterfølgende stigning i den dopaminerge stimulation, kan medføre de dopaminerge bivirkninger, som er observeret efter behandling med COMT-hæmmere.
The consequent increase in dopaminergic stimulation can lead to the dopaminergic adverse reactions observed after treatment with COMT inhibitors.
Den eksakte metaboliske omsætning af ustekinumab kendes ikke.
The exact metabolic pathway for ustekinumab is unknown.
Den eksisterende kliniske erfaring er for begræ nset til at udelukke en risiko, og Flixabi bør derfor ikke anvendes under graviditet.
The available clinical experience is too limited to exclude a risk, and administration of Flixabi is therefore not recommended during pregnancy.
Den eksisterende kliniske erfaring er for begrænset til at udelukke en risiko, og administration af infliximab bør derfor ikke anvendes under graviditeten.
The available clinical experience is too limited to exclude a risk, and administration of infliximab is therefore not recommended during pregnancy.
Den eksisterende kliniske erfaring er for begrænset til at udelukke en risiko, og indgift af infliximab anbefales derfor ikke under graviditet.
The available clinical experience is too limited to exclude a risk, and administration of infliximab is therefore not recommended during pregnancy.
Den eksterne kontrolgruppe bestod af 86 patienter behandlet med tilgængelig terapi (som ovennævnt) på omtrent samme tidspunkt og på de samme afdelinger, som patienterne behandlet med posaconazol.
86 patients treated with available therapy (as above) mostly at the same time and at the same sites as the patients treated with posaconazole.
Den ekstrapankreatiske virkning er f.eks. en øget insulinfølsomhed i de perifere væv og et fald i leverens insulinoptagelse.
Extrapancreatic effects include an improvement in insulin sensitivity of peripheral tissue and a reduction in hepatic uptake of insulin.
Den elektroniske injektionsindretning til cylinderampullerne er programmeret til at give de korrekte doser Rebif ved behandlingens start og under standarddosisfasen.
The electronic injection device used with the cartridges is programmed to deliver the correct doses of Rebif at the start of treatment and during the standard-dose phase.
Den eller de stammer (højst to stammer), som inkluderes i den endelige vaccine, vil blive udvalgt baseret på den givne epidemiologiske situation på fremstillingstidspunktet og vil blive deklareret på pakningen og i indlægssedlen.
The type of strain(s) (two strains at most) included in the final product will be selected based on the epidemiological situation at the time of manufacturing and will be stated on the package and in the package leaflet
Den eller de stammer (højst to stammer), som inkluderes i den endelige vaccine, vil blive udvalgt baseret på den givne epidemiologiske situation på fremstillingstidspunktet og vil blive deklareret på pakningen og i indlægssedlen.
The type of strain(s) (two strains at most) included in the final product will be selected based on the epidemiological situation at the time of manufacturing and will be stated on the package and in the package leaflet.
Den embryo- føtale toksicitet blev evalueret hos rotter og kaniner.
Embryo-foetal toxicity was evaluated in rats and rabbits.
Den embryo- føtale toksicitet blev evalueret hos rotter og kaniner.
Embryofoetal toxicity was evaluated in rats and rabbits.
Den emulsion, der dannes, kan derefter indsprøjtes.
The resulting ‘emulsion’ is then injected.
Den endelig formulering efter den radioaktive mærkning indeholder 2,08 mg [90Y] ibritumomab tiuxetan i en samlet volumen på 10 ml.
The final formulation after radiolabelling contains 2.08 mg [90Y] ibritumomab tiuxetan in a total volume of 10 ml.
Den endelige
The final study
Den endelige [90Y] radioaktivt mærkede Zavalin-opløsning indeholder op til 28 mg natrium pr. dosis afhængig af koncentrationen af radioaktivitet.
The final [90Y]-radiolabelled Zevalin solution contains up to 28 mg sodium per dose, depending on the radioactivity concentration.
Den endelige analyse af OS blev gennemført, efter at 218 hændelser (dødsfald) var forekommet og viser en tendens til en øgning i median overlevelse på 5,5 måneder i cabozantinib-armen: Median (måneder) 26,6 for cabozantinib vs.
The final analysis of OS was conducted after 218 events (deaths) occurred and shows a trend for an increase in median survival of 5.5 months in the cabozantinib arm: median (months) 26.6 cabozantinib vs.
Den endelige analyse af samlet overlevelse (12. januar 2015) viste en statistisk signifikant forbedring af samlet overlevelse af kombinationen sammenlignet med dabrafenib-monoterapi (figur 1).
The final OS analysis (12 January 2015) demonstrated a statistically significant improvement in OS for the combination compared with dabrafenib monotherapy (Figure 1).
Den endelige analyse af samlet overlevelse blev udført, da 389 patienter var døde (221 i placebo- gruppen og 168 i Perjeta-gruppen).
The final analysis of OS was performed when 389 patients had died (221 in the placebo-treated group and 168 in the Perjeta-treated group).
Den endelige analyse blev udført, da alle patienter havde nået deres 10 års follow-up-besøg (medmindre de havde DFS eller udgik tidligere fra follow-up).
The final analysis was performed when all patients had reached their 10-year follow-up visit (unless they had a DFS event or were lost to follow up before).
Den endelige analyse blev udført, da alle patienter havde nået deres 10 års follow-up-besøg (medmindre de havde en DFS eller udgik tidligere fra follow-up).
The final analysis was performed when all patients had reached their 10-year follow-up visit (unless they had a DFS event or were lost to follow-up before).
Den endelige analyse blev udført, da alle patienter havde nået deres 10 års followup besøg (medmindre de havde en DFS hændelse eller tidligere udgik af followup).
The final analysis was performed when all patients had reached their 10-year follow-up visit (unless they had a DFS event or were lost to follow- up before).
Den endelige analyse blev udført, da alle patienter havde nået deres 10 års followup besøg (medmindre de havde en DFS hændelse eller tidligere udgik af followup).
The final analysis was performed when all patients had reached their 10-year follow-up visit (unless they had a DFS event or were lost to follow-up before).
Den endelige analyse blev udført, da alle patienter havde nået deres 10 års followup-besøg (medmindre de havde DFS eller udgik tidligere fra followup).
The final analysis was performed when all patients had reached their 10-year follow-up visit (unless they had a DFS event or were lost to follow- up before).
Den endelige analyse blev udført, da alle patienter havde nået deres 10 års followup-besøg (medmindre de havde DFS eller udgik tidligere fra followup).
The final analysis was performed when all patients had reached their 10-year follow-up visit (unless they had a DFS event or were lost to follow-up before).
Den endelige analyse blev udført, da alle patienter havde nået deres 10 års followup-besøg (medmindre de havde DFS-hændelse eller udgik tidligere fra followup).
The final analysis was performed when all patients had reached their 10-year follow-up visit (unless they had a DFS event or were lost to follow- up before).
Den endelige analyse blev udført, da alle patienter havde nået deres 10 års followup-besøg (medmindre de havde en DFS hændelse eller tidligere udgik af followup).
The final analysis was performed when all patients had reached their 10-year follow-up visit (unless they had a DFS event or were lost to follow-up before).
Den endelige analyse blev udført, da elle patienter havde nået deres 10 års follow-up-besøg (medmindre de havde DFS eller udgik tidligere fra follow-up).
The final analysis was performed when all patients had reached their 10-year follow-up visit (unless they had a DFS event or were lost to follow-up before).
Den endelige analyse udføres, når studiet omfatter mindst 40 patienter med påvist RET-mutation og 40 patienter uden dokumentation for RET- mutation, og de har fået vandetanib i 14 måneder.
The final analysis will be performed when at least 40 patients identified with RET mutation and 40 patients identified without evidence of RET mutation have been enrolled into the study and received vandetanib for 14 months.
Den endelige effektanalyse inkluderede alle patienter randomiseret til begge dele af studiet.
The final efficacy analysis included all patients randomized to both parts of the trial.
Den endelige formulering efter radioaktiv mærkning indeholder 2,08 mg ibritumomab tiuxetan [90Y] i et totalt volumen på 10 ml.
The final formulation after radiolabelling contains 2.08 mg ibritumomab tiuxetan [90Y] in a total volume of 10 ml.
Den endelige halveringstid var dog kortere hos overfølsomme patienter end hos patienter, der ikke var overfølsomme, og den kan være nedsat på grund af dannelse af en høj koncentration af antistoffer mod lægemidlet.
However, terminal half-life was shorter in hypersensitive patients than in non-hypersensitive patients, and may be decreased due to the formation of high levels of anti-drug antibodies.
Den endelige infusionsopløsning skal indgives så tæt på klargøringstidspunktet som muligt.
The final infusion solution should be administered as close to preparation time as possible.
Den endelige koncentration af Defitelio skal være mellem 4 mg/ml og 20 mg/ml (se pkt.
The final concentration of Defitelio should be in the concentration range of 4 mg/mL – 20 mg/mL (see section 6.3).
Den endelige koncentration af skummetmælkspulveret skal være 5 g/l.
The final concentration of the skimmed milk powder should be 5 g/l.
Den endelige koncentration af skummetmælkspulveret skal være 5 g/l.
The final concentration of the skimmed milk powder should be 5 g/litre.
Den endelige koncentration bør være mellem 2 mg og 10 mg belatacept per ml opløsning.
The concentration of belatacept in the infusion should be between 2 mg and 10 mg belatacept per ml solution.
Den endelige opløsning skal være klar til let opaliserende, farveløs til lysegul.
The resulting solution should be clear to slightly opalescent, colourless to slightly yellow.
Den endelige påvisning af zoster-tilfælde blev foretaget ved hjælp af polymerasekædereaktion (PCR) [86 %] eller ‒ hvis virus ikke kunne påvises ‒ i henhold til den kliniske bedømmelseskomites vurdering [14 %].
Final determination of zoster cases was made by Polymerase Chain Reaction (PCR) [86%], or in the absence of virus detection, as determined by a clinical evaluation committee [14%].
Den endelige rapport forventes i første kvartal af 2018.
The final report is expected in Q1 2018.
Den endelige salgsudgave består af en papæske indeholdende enten to eller fem implantatorer pakket enkeltvist i folie, som er blevet steriliseret, sammen med et implantationsudstyr (aktivator), som ikke er blevet steriliseret.
Cardboard carton containing either two or five individually foil wrapped implanters that have been sterilised, together with an implanting device (actuator) that is not sterilised.
Den endelige studierapport skal indsendes senest 31. marts 2017
The final clinical study report should be submitted by 31st March 2017
Den endelige studierapport skal indsendes senest 31. oktober 2016
The final clinical study report should be submitted by 31st October 2016
Den endelige undersøgelsesrapport skal forelægges senest den
The final study report shall be submitted by
Den endelige, blandede og fortyndede opløsning er stabil i 24 timer ved højst 25 °C.
The reconstituted and diluted solution is stable for 24 hours at 25C.
Den endelige, radiomærkede injektionsopløsning skal beskyttes mod oxygen.
The final radiolabelled injection solution must be protected from oxygen.
Den ene af undersøgelserne omfattede patienter over 12 år, mens den anden omfattede patienter mellem seks og 12 år.
One of the studies was in patients aged over 12 years, while the other involved patients aged between six and 12 years.
Den ene hovedundersøgelse omfattede 676 patienter med fremskredent melanom, som tidligere var blevet behandlet, og hos hvem behandlingen ikke virkede eller ikke længere virkede.
One main study involved 676 patients with advanced melanoma that had been previously treated and in whom the treatment had not worked or had stopped working.
Den ene patient med manglende effekt under behandlingen afbrød behandlingen før det planlagte tidspunkt på grund af en bivirkning.
The one patient with on-treatment failure discontinued treatment early due to an adverse event.
Den ene pen giver doser på 5 mikrogram, og den anden giver doser på 10 mikrogram.
One to deliver doses of 5 micrograms and one 10 micrograms.
Den ene side af tabletten er præget med tallet "15".
One side of the tablet is debossed with “ 15”.
Den ene side er mærket ”54 193”, med en markeringslinje mellem ”54” og ”193”.
One side is marked with the code “54 193”, with a single bisect separating the “54” and “193”.
Den ene side er præget med koden ”54 193”, med en markeringslinje mellem ”54” og ”193”.
One side is embossed with the code “54 193”, with a single bisect separating the “54” and “193”.
Den ene undersøgelse omfattede 1 083 patienter, hovedsagelig med nyreinfektioner eller i visse tilfælde komplicerede urinvejsinfektioner.
One study involved 1,083 patients who mostly had kidney infection or in some cases a complicated urinary-tract infection.
Den ene URM, som modtog 84 mg to gange dagligt, havde ikke en tilstrækkelig klinisk respons.
The one URM who received 84 mg twice daily did not have an adequate response.
Den eneste bivirkning, der ofte medførte seponering af Tasmar i kliniske undersøgelser, var diarré (se afsnit 4.4).
The only adverse reactions commonly leading to discontinuation of Tasmar in clinical trials was diarrhoea (see section 4.4).
Den eneste hyppige bivirkning i undersøgelser med Cinryze (som optræder hos mellem 1 og 10 patienter ud af 100) er udslæt, som ikke er alvorligt, og som typisk omfatter armene, brystet, maven eller injektionsstedet.
The only common side effect seen in studies with Cinryze (seen in between 1 and 10 patients in 100) is rash, which is not serious and typically involves the arms, chest, abdomen or the injection site.
Den eneste indberettede bivirkning er hypotension.
The only adverse event reported to date was hypotension.
Den eneste observerede interaktion mellem linagliptin og metformin var, at kropsvægten ikke steg i samme grad.
The only observed interaction between linagliptin and metformin was a reduction of body weight gain.
Den enkelte flaske skal kasseres efter 3 dage.
Each bottle should be discarded after 3 days.
Den enkelte patient kan variere i deres respons på faktor VIII, og således udvise forskellige halveringstider og bedringer.
Individual patients may vary in their response to factor VIII, demonstrating different half-lives and recoveries.
Den enkelte patients CFA-72t-værdi fra placebobehandling blev anvendt som vedkommendes ikke-behandlingsværdi for CFA-72t.
Each patient’s CFA-72h during placebo treatment was used as their no-treatment CFA-72h value.
Den er almindeligvis forbigående og forsvinder normalt i løbet af to uger.
This is generally reversible and will usually disappear within two weeks.
Den er baseret på Deres størrelse (højde og vægt), og om De har en tilbagevendende svulst, og hvorvidt De tidligere har fået kemoterapi.
This is based on your size (height and weight) and if you have a recurrent tumour and have had chemotherapy treatment in the past.
Den er baseret på din størrelse (højde og vægt), og om du har en tilbagevendende svulst, og hvorvidt du tidligere har fået kemoterapi.
This is based on your size (height and weight) and if you have a recurrent tumour and have had chemotherapy treatment in the past.
Den er beregnet til at blive givet før eller under den næste pandemiske influenza for at forebygge influenza forårsaget af virus af typen H5N1.
It is intended to be given before or during the next pandemic influenza (flu) to prevent flu caused by the H5N1 type of the virus.
Den er beregnet til at stimulere aktiv immunitet mod PCV2 og Mycoplasma hyopneumoniae hos grise.
It is intended to stimulate active immunity against PCV2 and Mycoplasma hyopneumoniae in pigs.
Den er bundet til plasmaproteiner i højere grad end toremifen, idet den proteinbundne fraktion er
It is bound to plasma proteins even more extensively than toremifene, the protein bound fraction being
Den er dannet under indvirkning af CYP3A4 og CYP2D6.
It is formed under the action of CYP3A4 and CYP2D6.
Den er elimineret fra plasmaen på 5 til 7 dage.
It is eliminated from the plasma in 5–7 days.
Den er karakteriseret ved utilstrækkelig -galaktosidase.
It is characterised by the deficiency of -galactosidase.
Den er klar eller let opaliserende og farveløs eller svagt gul.
It is clear to slightly opalescent and colourless or pale yellow liquid.
Den er mærket ned 3 forskellige doser: 30 mg, 45 mg og 60 mg
It is marked with three different doses: 30 mg, 45 mg and 60 mg.
Den er specielt designet til at holde glasset og sprøjten fast, mens du forbereder Enbrel-injektionsvæsken.
It is specially designed to hold the vial and syringe in place while preparing the Enbrel solution.
Den er strukturelt identisk med den humane FXIII A- subunit [A2].
It is structurally identical to the human FXIII A-subunit [A2].
Den er udløbet (se figur E).
It is expired (Figure E).
Den estimerede 2-års kumulative risiko for progression til AML var 13,8 % hos patienter med en isoleret Del (5q)-anomali, sammenlignet med 17,3 % hos patienter med Del (5q) og en ekstra cytogenetisk anomali, og 38,6 % hos patienter med en kompleks karyotype.
The estimated 2-year cumulative risk of progression to AML were 13.8% in patients with an isolated Del (5q) abnormality compared to 17.3% for patients with Del (5q) and one additional cytogenetic abnormality and 38.6% in patients with a complex karyotype.
Den estimerede 3-års sandsynlighed for, at pneumoni rapporteres som en bivirkning, var 12,3 % for placebo, 13,3 % for salmeterol, 18,3 % for FP og 19,6 % for salmeterol/fluticasonpropionat (hazard ratio for fluticasonpropionat/salmeterol vs. placebo: 1,64; 95 % CI: 1,33-2,01; p<0,001).
The estimated 3-year probability of having pneumonia reported as an adverse event was 12.3% for placebo, 13.3% for salmeterol, 18.3% for FP and 19.6% for salmeterol/fluticasone propionate (hazard ratio for fluticasone propionate/salmeterol vs placebo: 1.64, 95% CI: 1.33 to 2.01, p<0.001).
Den estimerede 4-års OS hos kohorte 5- patienter var 83,6 % sammenlignet med 44,8 % i den historiske kontrolgruppe.
The estimated 4-year OS in cohort 5-patients was 83.6 % compared to 44.8 % in the historical controls.
Den estimerede 4-års OS hos kohorte 5- patienter var 83,6% sammenlignet med 44,8% i den historiske kontrolgruppe.
The estimated 4-year OS in cohort 5-patients was 83.6% compared to 44.8% in the historical controls.
Den estimerede 60-måneders rate for progressionsfri overlevelse var 88,9% (CI: 84% - 92,4%) for både dasatinib- og imatinib-armene.
The estimated 60-month PFS rate was 88.9% (CI: 84% - 92.4%) for both the dasatinib and imatinib treatment groups.
Den estimerede behandlingsforskel for ivacaftor versus placebo var 1,7 procentpoints (95 % CI -0,6; 4,1), denne forskel var ikke statistisk signifikant (P = 0,15).
The estimated treatment difference for ivacaftor versus placebo was 1.7 percentage points (95% CI -0.6, 4.1); this difference was not statistically significant (P = 0.15).
Den estimerede dosis, som spædbarnet fik fra mælken (forudsat, at mælkeindtagelsen var på 150 ml/kg dagligt) fra kvinder, der fik 300 mg dagligt eller den maksimale dosis på 600 mg dagligt, ville være henholdsvis 0,31 eller 0,62 mg/kg dagligt.
The estimated infant dose from breast milk (assuming mean milk consumption of 150 ml/kg/day) of women receiving 300 mg/day or the maximum dose of 600 mg/day would be 0.31 or
Den estimerede effekt af vaccinen i løbet af STPS-opfølgningsperioden var 40 % (95 % CI: [18 til 56 %]) for zostertilfælde, 60 % (95 % CI: [-10 til
The estimated vaccine efficacy during the STPS follow-up period was 40% (95% CI: [18 to 56%]) for zoster incidence, 60% (95% CI:
Den estimerede frekvens af 2-års progression til AML hos patienter med en isoleret Del (5q)-anomali var 13,8 %, sammenlignet med 17,3 % hos patienter med Del (5q) og en yderligere cytogenetisk anomali.
The estimated 2-year rate of progression to AML in patients with an isolated Del (5q) abnormality was 13.8%, compared to 17.3% for patients with Del (5q) and one additional cytogenetic abnormality.
Den estimerede median for halveringstid for MabThera subkutan formulering var 29,7 dage (9,9 til
The estimated median terminal elimination half-life of MabThera subcutaneous formulation was
Den estimerede mediane terminale eliminationshalveringstid af MabThera var 22 dage (spændvidde 6, 1- 52 dage).
The estimated median terminal elimination half-life of MabThera was 22 days (range, 6.1 to 52 days).
Den estimerede progressionsfrie rate efter 6 måneder var 98,4 % for everolimus-armen og 83,4 % for placebo-armen.
Estimated progression-free rates at 6 months were 98.4% for the everolimus arm and 83.4% for the placebo arm.
Den estimerede recidivrate ved udgangen af uge 26 var 7,12 % for Abilify Maintena og 7,76 % for oralt aripiprazol 10-30 mg (tabletter), svarende til en difference på -0,64 %.
The estimated relapse rate by end of Week 26 was 7.12 % for Abilify Maintena , and 7.76 % for oral aripiprazole tablets 10-30 mg , a difference of -0.64 %.
Den europæiske offentlige vurderingsrapport (EPAR) for Exubera kan ses i sin helhed her.
The full EPAR for Exubera is available here.
Den evne insulin aspart har til at sænke blodglucosen, skyldes det faciliterede optag af glucose, efter at insulin er bundet til receptorer på muskel- og fedtceller, og den samtidige inhibering af glucose- frigivelse fra leveren.
The blood glucose lowering effect of insulin aspart is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.
Den evne Levemir har til at sænke blodglucose, skyldes den faciliterede optagelse af glucose, efter at insulin er bundet til receptorer på muskel- og fedtceller, og den samtidige inhibering af glucose- frigivelse fra leveren.
The blood glucose lowering effect of Levemir is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.
Den evne Levemir har til at sænke blodglucosen, skyldes den faciliterede optagelse af glucose, efter at insulin er bundet til receptorer på muskel- og fedtceller, og den samtidige inhibering af glucose- frigivelse fra leveren.
The blood glucose lowering effect of Levemir is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.